1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

  • September 2017
  • 282 pages
  • ID: 3596607

Summary

Table of Contents

• The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.
• The global noncancer market is expected to grow from $1.3 billion in 2017 to $2.6 billion in 2022 at a CAGR of 15.2% for the period 2017-2022.
• The global cancer market is expected to grow from $229.3 million in 2017 to $1.9 billion in 2022 at a CAGR of 52.4% for the period 2017-2022.

Chapter 1: Introduction
Study Goals and Objectives
BCC Research’s goal for this study is to provide an in-depth update study of the liquid biopsy diagnostics industry, an emerging industry with high market potential. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geography. The market sizes are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

Market segments that provide exceptional growth opportunities include cancer therapy guidance and monitoring and organ transplant surveillance.

The report provides a comprehensive discussion of liquid biopsy technologies, clinical applications, industry structure, liquid biopsy funding initiatives, global markets, patent status and companies. The report is designed to provide an in-depth analysis of the industry and markets and aid companies in their strategic planning efforts relating to life science tools and diagnostics.

Reasons for Doing This Study
Traditional biopsy methods are often invasive, uncomfortable and carry risks of side effects. Liquid biopsy addresses these issues because it is noninvasive and carries little, if any, side effect risks.

In the age of genomics and personalized medicine, it is critical for clinicians to have diagnostic tools that can be used on a regular basis to screen, monitor, conduct surveillance, guide treatment or otherwise give valuable genomic information about a disease. Liquid biopsy provides this capability and thus is of high interest to the medical community.

Liquid-biopsy-enabling technologies are coming to the forefront and provide significant market growth momentum to the industry. Downstream analysis technologies like next-generation sequencing and digital polymerase chain reaction (PCR) are progressing in capabilities, efficiency, and costs. Upstream technologies like microfluidics, cell-free deoxyribo nucleic acid (DNA) capture and isolation, cell capture, and DNA amplification are also making significant progress.

Liquid biopsy is also gaining significant traction with key opinion leaders, medical societies and insurance payors.

As a result, liquid biopsy is penetrating into attractive clinical applications, including average-risk noninvasive prenatal testing and cancer therapy guidance and monitoring.

Based on these trends, liquid biopsy markets are rapidly emerging and the need for industry and market characterization is great.

The outstanding growth potential for liquid biopsy diagnostics makes it particularly timely for preparing this updated report.

Scope of Report
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. It then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. Market driving forces are also discussed.

The structure of several important industry subsectors is reviewed, as well as major industry acquisitions and strategic alliances from January 2016 through July 2017. Industry subsectors analyzed include next- generation sequencing (NGS) instruments, droplet digital PCR, target enrichment and amplification, single-cell DNA polymerase, prenatal screening, liquid biopsy, direct to consumer, and clinical laboratory.

The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia-Pacific, Rest of World). Market data cover the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).
More than 165 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2016 through July 2017, including key alliance trends.

Information Sources
BCC Research performed both primary and secondary research for this report. Primary sources included industry companies and leading research institutions and secondary sources included company websites and industry, trade and government publications.

Methodology
Both primary and secondary sources were consulted for this report, and a study of the industry trends was performed. BCC Research examined each of the key end–user market segments that will be commercially important during the forecast period: cancer, transplant medicine and reproductive health.

Based on this analysis, the current and future applications of liquid biopsy products are evaluated in each of the major clinical market segments and historical sales revenues are given for 2015 and 2016, estimated revenues are given for 2017, and forecast revenues are given for 2022.

Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:

North America
• U.S.
• Mexico.
• Canada.

Europe
• Austria.
• Belgium.
• Czech Republic.
• Denmark.
• Estonia.
• France.
• Finland.
• Germany.
• Greece.
• Hungary.
• Iceland.
• Italy.
• Ireland.
• Luxembourg.
• Netherlands.
• Norway.
• Poland.
• Portugal.
• Romania.
• Spain.
• Sweden.
• Switzerland.
• Turkey.
• U.K.

Asia-Pacific
• Australia.
• China.
• Hong Kong.
• India.
• Japan.
• Malaysia.
• New Zealand.
• Philippines.
• Singapore.
• South Korea.

• Taiwan.
• Thailand.

Rest of World
• Argentina.
• Brazil.
• Chile.
• Israel.
• Kuwait.
• Russia.
• Saudi Arabia.
• South Africa.
• United Arab Emirates.

Liquid Biopsy Market, by Application
Cancer
Reproductive Health
Transplant Medicine

Liquid Biopsy Market, by Biomarker Type
Nucleic Acids
Cells
Extracellular Vesicles
Proteins

Liquid Biopsy Market, by Analysis Platform
Microarray
NGS
PCR
Proteomics
Other

Liquid Biopsy Market, by Analysis Purpose
Screening/Early Detection
Diagnosis
Therapy Guidance
Monitoring

Chapter 2: Summary and Highlights
Liquid biopsy is rapidly gaining traction as a supplement or alternative to doing a tissue biopsy for applications in reproductive health, cancer and transplant medicine. The liquid biopsy captures and analyzes biomarkers, mostly cell-free DNA, found in body fluids, most often in blood.

In the noninvasive prenatal testing market, liquid biopsy has achieved significant penetration in the high-risk pregnancy segment and is moving into the low-risk sector.

In cancer, liquid biopsy is gaining significant market traction. Two trends stand ou agnostic labeling strategy for cancer drugs is driving the use of liquid biopsy companion diagnostics. An example of the former trend is the agreement in June 2017 by the U.S. Department of Veterans Affairs to provide a liquid biopsy test, PlasmaSelect 64, to advanced cancer patients being treated at its facilities.

An example of the latter trend is the expanded approval in May 2017 by the U.S. Food and Drug Administration (FDA) of the checkpoint inhibitor drug Keytruda (Merck, pembrolizumab) for advanced cancer patients with microsatellite instability or mismatch repair deficiency. This approval highlighted a new paradigm in cancer care, where the patient is treated based on specific genomic defects rather than on the organ of origin. This will boost the market for molecular diagnostics that can detect these genomic markers and be used to guide treatment decisions associated with these drugs.

The global liquid biopsy market is estimated to be $1.5 billion in 2017 and is growing at a compound annual growth rate 24.2% to reach a forecast size of $4.5 billion by the year 2022.

The two main applications for liquid biopsy are cancer and noncancer (reproductive health and organ transplant diagnostics).

The global cancer market is estimated to be $229.3 million in 2017 and is growing at a compound annual growth rate of 52.4% to reach a forecast size of almost $1.9 billion by 2022.

Key growth sectors in the liquid biopsy cancer market include tests for lung cancer, pan-cancer tests that can detect cancer recurrence, and tests that can provide real-time assessment of disease progression or drug response. Liquid biopsy gives physicians a key tool for assessing whether a patient is taking the right drug in light of a wider choice of therapies coming onto the market.

The global noncancer market is estimated at nearly $1.3 billion in 2017 and is growing at a compound annual growth rate of 15.2% to reach a forecast size of $2.6 billion by 2022.

Driving this market has been the success of noninvasive prenatal testing (NIPT) for high-risk pregnancies.
Test providers are focusing on the low-risk sector as well as on test differentiation as strategies to maintain growth.

A third high-potential market sector for liquid biopsy is for organ transplantation diagnostics. In this market, there is a strong need for noninvasive diagnostics that can detect the early onset of organ rejection so that immunosuppression can be optimized.

Circulating cell-free DNA is fast emerging as the predominant biomarker for liquid biopsy for all market segments. This creates a market opportunity for companies who have or can develop proprietary technologies for improving the workflow for capturing, detecting and analyzing this biomarker type.

The liquid biopsy industry is dynamic and gaining substantial traction in its three main clinical market segments. This report provides a comprehensive overview and analysis of this industry, which is undergoing exceptional growth and promises to transform medical treatment and surveillance strategies.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Lung Cancer Liquid Biopsy Market 2017-2021

Lung Cancer Liquid Biopsy Sector: Worldwide Forecast until 2021

  • $ 2500
  • Industry report
  • November 2017
  • by Infiniti Research Limited

About Lung Cancer Liquid BiopsyA liquid biopsy helps to identify free-floating tumor DNA (also known as circulating DNA) within the blood sample of a patient. Lung cancer liquid biopsy helps to detect ...

Global POC Molecular Diagnostics Market 2017-2021

POC Molecular Diagnostics Sector: Worldwide Forecast until 2021

  • $ 2500
  • Industry report
  • November 2017
  • by Infiniti Research Limited

About POC Molecular DiagnosticsPOC molecular diagnostics help in identification, treatment, and prevention of infectious diseases, oncology, hematology, and prenatal diseases. The demand for POC molecula ...

Liquid Biopsy Market: Rising Cases of Lung Cancer Fuelling Adoption of Liquid Biopsy Across the World: Global Industry Analysis (2012 - 2016) and Opportunity Assessment (2017 - 2027)

Liquid Biopsy Market: Rising Cases of Lung Cancer Fuelling Adoption of Liquid Biopsy Across the World: Global Industry Analysis (2012 - 2016) and Opportunity Assessment (2017 - 2027)

  • $ 5000
  • Industry report
  • November 2017
  • by Future Market Insight Global & Consulting Pvt Ltd

This Future Market Insights (FMI) report examines the global liquid biopsy market for the period 2017–2027. The primary objective of the report is to offer insights into developments in the liquid biopsy ...


Download Unlimited Documents from Trusted Public Sources

Global Diagnostics Forecast Statistics

  • January 2018
    26 pages
  • Diagnostics  

    Cervical Cancer  

  • World  

View report >

Prostate Cancer Statistics in the US - Forecast

  • December 2017
    2 pages
  • Prostate Cancer  

    Biopsy  

  • United States  

    North America  

View report >

Laboratory and Biopsy Statistics in the UK

  • November 2017
    49 pages
  • Laboratory  

    Biopsy  

    HPV Testing  

  • United Kingdom  

    Europe  

View report >

Related Market Segments :

Biopsy

ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on